Hypothesis

Biomarker‑triggered intermittent dasatinib + quercetin (D+Q) dosing, initiated when circulating senescence‑associated extracellular vesicle (EV) miRNAs (miR‑146a, miR‑21, let‑7a) exceed a validated threshold, will achieve greater senescent cell clearance, lower inflammatory burden, and attenuate rebound senescence compared with a standard every‑2‑weeks fixed schedule.

Rationale

• D+Q eliminates senescent cells by simultaneously targeting tyrosine‑kinase–dependent and BCL‑2‑family‑dependent anti‑apoptotic pathways [1].
• Intermittent dosing already shows lifespan and functional benefits [2, 3] but relies on arbitrary calendars that ignore individual variation in senescent cell accumulation.
• Senescent cells alter EV cargo, enriching specific miRNAs (miR‑146a, miR‑21, let‑7a) that mirror SASP intensity [7]. These EVs are readily detectable in plasma, offering a non‑invasive readout of senescence load.
• We posit that SASP‑derived miRNAs not only reflect but also feed back to promote paracrine senescence in neighboring cells; thus, clearing senescent cells when their EV‑miRNA signal peaks should interrupt this feed‑forward loop, reducing the emergence of new senescence (the “rebound” concern).

Novel Mechanistic Insight

1. EV‑miRNA as a rheostat – High circulating miR‑146a/miR‑21/let‑7a indicates a tissue microenvironment where SASP‑mediated NF‑κB activation is sustaining senescence. Removing the source cells at this point should cause a rapid drop in these miRNAs, breaking the autocrine/paracrine reinforcement.
2. Adaptive interval lengthening – After each D+Q cycle, the EV‑miRNA signal will fall below threshold; the next dose is delayed until it rises again. This creates a personalized dosing interval that lengthens as senescent burden declines, minimizing drug exposure while maintaining efficacy.
3. Prevention of compensatory senescence – Fixed schedules may hit tissues when senescent cell numbers are low, inadvertently selecting for resistant senescent phenotypes or triggering stress‑induced premature senescence via off‑target effects. Biomarker triggering aligns drug exposure with the window of maximal senescent‑cell dependency on D+Q‑sensitive survival pathways, reducing selective pressure for resistance.

Testable Predictions

• Primary outcome: In naturally aged mice (20‑month-old), biomarker‑guided D+Q will reduce p16^Ink4a^+ cell frequency by ≥30% more than fixed‑interval D+Q in liver, kidney, and brain after 3 months of treatment.
• Secondary outcomes:
  • Plasma EV‑miR‑146a, miR‑21, let‑7a levels will show larger amplitude drops post‑treatment in the biomarker group.
  • Serum SASP cytokines (IL‑6, TNF‑α, MCP‑1) will be lower at matched time points.
  • Histological markers of tissue fibrosis (collagen I area) and neuroinflammation (Iba1^+ microglia) will be improved.
  • Incidence of new p16^Ink4a^+ cells appearing after treatment cessation (measured at 4‑week washout) will be significantly lower in the biomarker group, indicating attenuated rebound senescence.
• Safety: No increase in liver enzymes, hematologic toxicity, or weight loss beyond that seen with fixed dosing.

Experimental Design (Outline)

1. Animals: C57BL/6J mice, n=15 per group, aged 20 months.
2. Groups:
   • Control: vehicle.
   • Fixed D+Q: dasatinib 5 mg/kg + quercetin 50 mg/kg orally, days 3‑4 and 11‑12 of each 14‑day cycle (as in prior studies).
   • Biomarker‑guided D+Q: same dosing regimen, but administered only when plasma EV‑miR‑146a (or a composite score of the three miRNAs) exceeds the 75th percentile of baseline levels measured twice weekly.
3. Monitoring: Blood collected twice weekly for EV isolation (ultracentrifugation or size‑exclusion) and miRNA qPCR; senescence burden assessed via p16^Ink4a^‑Luciferase reporter (if available) or immunohistochemistry at baseline, 6 weeks, and 12 weeks.
4. Endpoints: As listed above; statistical analysis using mixed‑effects models to account for repeated measures.

Falsifiability

If biomarker‑guided D+Q fails to show superior senescent cell clearance, reduced SASP, or lower rebound senescence compared with fixed dosing—and instead shows equal or worse outcomes—the hypothesis is falsified. Conversely, demonstrating a clear advantage would support the concept of EV‑miRNA‑guided senolytic precision medicine.

Implications

Positive validation would justify developing a point‑of‑care EV‑miRNA assay to tailor senolytic cycles in humans, moving beyond blanket schedules toward individualized regimens that maximize benefit while limiting drug exposure and mitigating the risk of treatment‑induced resistance.